Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mink Therapeutics Inc
(NQ:
INKT
)
0.8183
+0.0083 (+1.02%)
Streaming Delayed Price
Updated: 2:43 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mink Therapeutics Inc
< Previous
1
2
3
4
Next >
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024
August 13, 2024
INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
MiNK Reports Second Quarter 2024 Results and Business Update
August 13, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
August 01, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
July 31, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Earnings Outlook For MiNK Therapeutics
March 20, 2024
Via
Benzinga
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
June 05, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
May 22, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024
May 14, 2024
INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
MiNK Reports First Quarter 2024 Results
May 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Why MiNK Therapeutics Stock Is Up 11% Monday
May 13, 2024
MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 13, 2024
Via
Benzinga
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
May 13, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
April 30, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
April 08, 2024
Via
Benzinga
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
April 08, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
April 05, 2024
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 05, 2024
Via
Benzinga
INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023
March 21, 2024
INKT stock results show that MiNK Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
MiNK Reports Fourth Quarter and Year-End 2023 Results
March 21, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
March 07, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Earnings Scheduled For March 21, 2024
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
March 06, 2024
MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
From
MiNK Therapeutics
Via
GlobeNewswire
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
February 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 06, 2024
Via
Benzinga
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
February 06, 2024
Treatment with agenT-797 Showed Improved Survival in Severe Respiratory Distress
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
January 30, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
December 20, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Third Quarter 2023 Results
November 09, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
November 03, 2023
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.